DK1212060T3 - Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom - Google Patents

Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom

Info

Publication number
DK1212060T3
DK1212060T3 DK00960782T DK00960782T DK1212060T3 DK 1212060 T3 DK1212060 T3 DK 1212060T3 DK 00960782 T DK00960782 T DK 00960782T DK 00960782 T DK00960782 T DK 00960782T DK 1212060 T3 DK1212060 T3 DK 1212060T3
Authority
DK
Denmark
Prior art keywords
dopa
drug
nicotine
disease
derivatives
Prior art date
Application number
DK00960782T
Other languages
Danish (da)
English (en)
Inventor
Pierre Cesaro
Gabriel Villafane
Original Assignee
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris filed Critical Assist Publ Hopitaux De Paris
Application granted granted Critical
Publication of DK1212060T3 publication Critical patent/DK1212060T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK00960782T 1999-09-02 2000-09-01 Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom DK1212060T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9911029A FR2798065B1 (fr) 1999-09-02 1999-09-02 Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
PCT/FR2000/002428 WO2001015696A1 (fr) 1999-09-02 2000-09-01 Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson

Publications (1)

Publication Number Publication Date
DK1212060T3 true DK1212060T3 (da) 2005-08-15

Family

ID=9549506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00960782T DK1212060T3 (da) 1999-09-02 2000-09-01 Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom

Country Status (10)

Country Link
US (1) US6911475B1 (pt)
EP (1) EP1212060B1 (pt)
AT (1) ATE292969T1 (pt)
CA (1) CA2383509C (pt)
DE (1) DE60019436T2 (pt)
DK (1) DK1212060T3 (pt)
ES (1) ES2241651T3 (pt)
FR (1) FR2798065B1 (pt)
PT (1) PT1212060E (pt)
WO (1) WO2001015696A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69912808T2 (de) 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
AU2001282064B2 (en) * 2000-08-03 2007-02-01 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) * 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
KR100421585B1 (ko) 2001-10-25 2004-03-09 한국전자통신연구원 시간분할 듀플렉스 시스템에서 이동국의 셀 탐색 시스템및 그 방법
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
PT1670433E (pt) 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
US7257577B2 (en) * 2004-05-07 2007-08-14 International Business Machines Corporation System, method and service for ranking search results using a modular scoring system
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
AU2011203482B2 (en) * 2007-04-02 2014-09-04 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
EP2322166A1 (en) * 2007-04-02 2011-05-18 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232933A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
ATE292969T1 (de) 2005-04-15
FR2798065B1 (fr) 2003-09-05
US6911475B1 (en) 2005-06-28
EP1212060A1 (fr) 2002-06-12
WO2001015696A1 (fr) 2001-03-08
EP1212060B1 (fr) 2005-04-13
CA2383509C (fr) 2012-08-14
CA2383509A1 (fr) 2001-03-08
ES2241651T3 (es) 2005-11-01
PT1212060E (pt) 2005-08-31
DE60019436T2 (de) 2006-02-02
DE60019436D1 (de) 2005-05-19
FR2798065A1 (fr) 2001-03-09

Similar Documents

Publication Publication Date Title
DK1212060T3 (da) Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
EP0513702A3 (en) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
FI935847A0 (fi) L-DOPA-esterkompositioner
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
WO2001001973A3 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
BG103521A (en) Substituted pyrimidinon and pyridon compounds and methods for their application
GEP20043303B (en) Polycycloalkylpurines as Adenosine Receptor Antagonists
PL339946A1 (en) Drug preparation in the form of a prolonged drug release tablet for treating parkinsonism
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
Wise Sertraline as a treatment for premature ejaculation.
KR970005283A (ko) 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도
Myers et al. Nocturnal cataclysms with myoclonus: a new side effect of clomipramine.
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
JPS57167922A (en) Psychotropic drug
KR930019207A (ko) 카르니틴 결핍 hiv-혈청양성 환자 치료용 l-카르니틴의 용도
RU2006137657A (ru) Применение производных камптотецина для лечения пролиферативных заболеваний с использованием схемы лечения с фиксированной дозой
HUP0204116A2 (hu) Eljárások az alacsony termet homeboxát tartalmazó (SHOX) génnel kapcsolatos alacsony termet növekedési rendellenességek kezelésére
RU93004536A (ru) Лекарство для профилактики и терапии неврологических и психиатрических нарушений, возникающих при употреблении алкоголя
YU9302A (sh) Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa
EP1797884A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system